TWI417114B - 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 - Google Patents

具有增強穩定性之弱水溶性藥物之組合物及其製備方法 Download PDF

Info

Publication number
TWI417114B
TWI417114B TW95132027A TW95132027A TWI417114B TW I417114 B TWI417114 B TW I417114B TW 95132027 A TW95132027 A TW 95132027A TW 95132027 A TW95132027 A TW 95132027A TW I417114 B TWI417114 B TW I417114B
Authority
TW
Taiwan
Prior art keywords
composition
docetaxel
certain embodiments
albumin
cancer
Prior art date
Application number
TW95132027A
Other languages
English (en)
Chinese (zh)
Other versions
TW200744677A (en
Inventor
Tapas De
Neil P Desai
Andrew Yang
Zachary Yim
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37700819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI417114(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of TW200744677A publication Critical patent/TW200744677A/zh
Application granted granted Critical
Publication of TWI417114B publication Critical patent/TWI417114B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/701—Integrated with dissimilar structures on a common substrate
    • Y10S977/702—Integrated with dissimilar structures on a common substrate having biological material component
    • Y10S977/705—Protein or peptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
TW95132027A 2005-08-31 2006-08-30 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 TWI417114B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71286505P 2005-08-31 2005-08-31
US73693105P 2005-11-14 2005-11-14
US73696205P 2005-11-14 2005-11-14

Publications (2)

Publication Number Publication Date
TW200744677A TW200744677A (en) 2007-12-16
TWI417114B true TWI417114B (zh) 2013-12-01

Family

ID=37700819

Family Applications (2)

Application Number Title Priority Date Filing Date
TW95132027A TWI417114B (zh) 2005-08-31 2006-08-30 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
TW95132009A TWI429452B (zh) 2005-08-31 2006-08-30 包含弱水溶性藥劑及抗微生物劑之組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW95132009A TWI429452B (zh) 2005-08-31 2006-08-30 包含弱水溶性藥劑及抗微生物劑之組合物

Country Status (24)

Country Link
US (7) US7771751B2 (enExample)
EP (5) EP2399573B1 (enExample)
JP (2) JP5461837B2 (enExample)
KR (1) KR101420445B1 (enExample)
CN (3) CN101291659A (enExample)
AU (1) AU2006284808B2 (enExample)
BR (1) BRPI0615265A8 (enExample)
CA (3) CA2620585C (enExample)
CY (2) CY1121461T1 (enExample)
DK (2) DK1931321T3 (enExample)
ES (4) ES2718323T3 (enExample)
HU (2) HUE042678T2 (enExample)
IL (3) IL189601A (enExample)
LT (2) LT3311805T (enExample)
NO (2) NO345390B1 (enExample)
NZ (1) NZ566696A (enExample)
PL (2) PL3311805T3 (enExample)
PT (2) PT3311805T (enExample)
RU (2) RU2451510C2 (enExample)
SI (2) SI3311805T1 (enExample)
TR (2) TR200801336T1 (enExample)
TW (2) TWI417114B (enExample)
WO (1) WO2007027819A2 (enExample)
ZA (1) ZA200802765B (enExample)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
SG113402A1 (en) * 1997-06-27 2005-08-29 American Bioscience Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP2006524632A (ja) 2002-12-09 2006-11-02 アメリカン バイオサイエンス、インコーポレイテッド 組成物及び薬物送達方法
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
AU2012201568B2 (en) * 2005-02-18 2014-07-31 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
KR101457834B1 (ko) 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
RU2483714C2 (ru) * 2007-03-07 2013-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
MX355683B (es) * 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
EP2201935B1 (en) * 2008-12-26 2020-07-08 Samyang Biopharmaceuticals Corporation Polymeric micelle composition containing a poorly soluble drug and preparation method of the same
SMT201900751T1 (it) * 2009-04-15 2020-03-13 Abraxis Bioscience Llc Composizioni nanoparticellari prive di prioni e metodi
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
WO2011082196A2 (en) * 2009-12-30 2011-07-07 Baxter International Inc. Rapid reconstitution for lyophilized-pharmaceutical suspensions
CA2790895C (en) * 2010-02-24 2016-08-23 Jan Jezek Protein formulations
ES2675212T3 (es) * 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011135580A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
US9402847B2 (en) 2011-04-01 2016-08-02 Astrazeneca Ab Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
ES2819204T3 (es) 2011-04-28 2021-04-15 Abraxis Bioscience Llc Administración intravascular de composiciones de nanopartículas y usos de las mismas
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
PH12014500965A1 (en) 2011-11-01 2014-06-30 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
GB201119173D0 (en) * 2011-11-07 2011-12-21 Fujifilm Mfg Europe Bv Porous tissue scaffolds
US20140329786A1 (en) 2011-11-30 2014-11-06 Astrazeneca Ab Combination treatment of cancer
US9585960B2 (en) 2011-12-14 2017-03-07 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
CA2869460C (en) 2012-04-04 2018-05-15 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
KR102222346B1 (ko) 2013-03-04 2021-03-02 아스트라제네카 아베 조합 치료
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
SG11201507234UA (en) 2013-03-14 2015-10-29 Abraxis Bioscience Llc Methods of treating bladder cancer
CN103734153B (zh) * 2014-01-20 2016-04-27 王德昌 一种含活性阿维菌素的水溶性生物杀虫剂及其制备方法
AU2015274408A1 (en) 2014-06-13 2017-01-12 Mayo Foundation For Medical Education And Research Treating lymphomas
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
CN108024999A (zh) 2015-06-29 2018-05-11 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CN108700566A (zh) 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 免疫原性调节的方法
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US11207392B2 (en) 2016-06-30 2021-12-28 Nantcell Inc. Coordinated multi-prong cancer therapy
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
AU2017318668A1 (en) 2016-09-01 2019-03-21 Mayo Foundation For Medical Education And Research Carrier-PD-L1 binding agent compositions for treating cancers
MX2019002564A (es) 2016-09-06 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
KR102486057B1 (ko) 2016-09-06 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
WO2018048815A1 (en) 2016-09-06 2018-03-15 Nantibodyfc, Llc Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
AU2017362730B2 (en) 2016-11-21 2021-04-08 Nant Holdings Ip, Llc Fractal combination therapy
CA3052803A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
US20200305426A1 (en) * 2017-11-03 2020-10-01 Emerald Kalama Chemical, Llc Boosters for antimicrobial, preservative and biocidal applications
WO2019090272A1 (en) 2017-11-06 2019-05-09 Flx Bio, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
CN107970210A (zh) * 2017-12-05 2018-05-01 湖北九州通中加医药有限公司 一种非预溶性多西他赛注射液
WO2019143606A1 (en) 2018-01-17 2019-07-25 Nantbio, Inc. Enhanced immunogenicity for gpi-anchored antigens
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN112188892A (zh) 2018-03-20 2021-01-05 阿布拉科斯生物科学有限公司 通过mTOR抑制剂和白蛋白的纳米颗粒的施用治疗中枢神经系统障碍的方法
WO2019200084A1 (en) * 2018-04-11 2019-10-17 Zhuhai Beihai Biotech Co., Ltd. Formulations and compositions of docetaxel
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US10478422B1 (en) 2018-12-14 2019-11-19 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
CN115003284A (zh) 2019-10-28 2022-09-02 阿布拉科斯生物科学有限公司 白蛋白和雷帕霉素的药物组合物
ES3037830T3 (en) * 2020-02-04 2025-10-07 Zhuhai Beihai Biotech Co Ltd Formulations of docetaxel
KR20230154864A (ko) 2021-03-05 2023-11-09 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 안정한 도세탁셀 알부민 나노입자 조성물
KR102576559B1 (ko) * 2021-06-14 2023-09-08 충북대학교 산학협력단 도세탁셀 및 아파티닙이 봉입된 알부민 나노입자 및 이의 용도
CA3236501A1 (en) * 2021-10-26 2023-05-04 Arthur JAFFEE Albumin protein for use as an emulsifier and drug carrier
EP4504215A1 (en) * 2022-02-11 2025-02-12 Sameer Sabir Compositions of and methods for a cold slurry having hyaluronic acid
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033552A1 (en) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US20050004002A1 (en) * 2002-12-09 2005-01-06 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US5334582A (en) 1988-06-22 1994-08-02 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
US4960799A (en) 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
US6018031A (en) 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6120805A (en) * 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DK0674510T3 (da) 1992-11-27 1999-05-10 Napro Biotherapeutics Inc Injicerbart præparat omfattende paclitaxel
AU5553894A (en) 1992-11-27 1994-06-22 F.H. Faulding & Co. Limited Injectable taxol composition
US6410374B1 (en) * 1992-12-26 2002-06-25 Semiconductor Energy Laborartory Co., Ltd. Method of crystallizing a semiconductor layer in a MIS transistor
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20070117862A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US20030133955A1 (en) 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5498421A (en) 1993-02-22 1996-03-12 Vivorx Pharmaceuticals, Inc. Composition useful for in vivo delivery of biologics and methods employing same
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030073642A1 (en) 1993-02-22 2003-04-17 American Bioscience, Inc. Methods and formulations for delivery of pharmacologically active agents
US6528067B1 (en) * 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
JP3423317B2 (ja) 1993-07-19 2003-07-07 アンジオジェネシス テクノロジーズ インコーポレイテッド 抗−血管形成性組成物およびそれにより被覆されたステント
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
DE4438577A1 (de) 1994-10-28 1996-05-02 Basf Ag Selbsttragende Dübelmasse für die chemische Befestigungstechnik
US5681846A (en) 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US6964947B1 (en) 1995-11-07 2005-11-15 Genentech, Inc. Stabilizing formulation for NGF
US6537539B2 (en) 1996-01-11 2003-03-25 Human Genome Sciences, Inc. Immune cell cytokine
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5637625A (en) 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
KR100330373B1 (ko) 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5731556A (en) 1996-09-30 1998-03-24 Ingersoll-Rand Company Muffler for pneumatic device
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
US20050019266A1 (en) 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
CH692322A5 (it) 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
SG113402A1 (en) 1997-06-27 2005-08-29 American Bioscience Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
ES2202901T3 (es) 1997-09-09 2004-04-01 Lyotropic Therapeutics, Inc. Particulas recubiertas, procedimiento para su fabricacion y uso.
US5925776A (en) 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
AR015516A1 (es) 1998-02-10 2001-05-02 Gensia Sicor Inc Composicion farmaceutica esteril para administracion parenteral y uso de la misma para preparar un medicamento
EP1059934B1 (en) 1998-02-27 2002-07-24 Biora Bioex AB Matrix protein compositions for wound healing
US6914130B2 (en) 1998-06-17 2005-07-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1100494A1 (en) 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6150423A (en) 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6140373A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
MXPA01006424A (es) 1998-12-23 2002-06-04 Idea Ag Formulacion mejorada para aplicacion topica no invasiva in vivo.
AU3469400A (en) 1999-01-05 2000-07-24 Clarence C. Lee Pharmaceutical compositions for treatment of diseased tissues
ATE283042T1 (de) 1999-01-28 2004-12-15 Dinesh Shantilal Patel Parenterale lösungen enthaltend propofol (2,6- diisopropylphenol) und 2.5-di-0-methyl-1.4;3.6- dianhydro-d-glucitol als lösungsmittel
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
EP1165046A1 (en) 1999-04-05 2002-01-02 Baxter International Inc. Propofol compositions containing preservative additives
US6100302A (en) 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
WO2000071079A2 (en) * 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
CN1149984C (zh) 1999-06-21 2004-05-19 健一制药株式会社 用于静脉注射的含有普鲁泊福的麻醉组合物
GB9920548D0 (en) 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
JP4745573B2 (ja) * 1999-09-17 2011-08-10 マルホ株式会社 抗菌医薬組成物
JP4601100B2 (ja) * 1999-11-08 2010-12-22 三生医薬株式会社 マスティックの油液を内包した軟カプセル
WO2001049268A1 (en) * 2000-01-05 2001-07-12 Imarx Therapeutics, Inc. Pharmaceutical formulations for the delivery of drugs having low aqueous solubility
WO2001072299A1 (en) 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
JP2003535884A (ja) 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
US20020041897A1 (en) 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20040033273A1 (en) 2001-02-14 2004-02-19 Ayurcore, Inc. Withasol and methods of use
US20030157161A1 (en) 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
AU2002354957A1 (en) * 2001-07-19 2003-03-03 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
BR0211905A (pt) * 2001-08-22 2004-09-21 Wyeth Corp Dialdeìdos de rapamicina
GB0120702D0 (en) 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Anaesthetic formulations
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
PL374283A1 (en) 2001-12-20 2005-10-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
US20040210289A1 (en) 2002-03-04 2004-10-21 Xingwu Wang Novel nanomagnetic particles
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
CN1448132A (zh) 2002-03-29 2003-10-15 艾斯·多伯法股份公司 改进的基于紫杉醇的抗肿瘤制剂
ITMI20020681A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
US20040009168A1 (en) 2002-04-05 2004-01-15 Elizabet Kaisheva Multidose antibody formulation
SI21222A (sl) * 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20040126360A1 (en) 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
KR20120068035A (ko) 2002-12-09 2012-06-26 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US6838569B2 (en) 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
US20040171560A1 (en) 2002-12-23 2004-09-02 Dabur Research Foundation Stabilized pharmaceutical composition
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
CN1268619C (zh) 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
RS20160203A1 (sr) 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050043272A1 (en) * 2003-07-11 2005-02-24 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20070148765A1 (en) 2003-11-19 2007-06-28 Evans Robert K Preservative-containing virus formulations
AU2004293075A1 (en) 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
US7012223B2 (en) 2003-11-25 2006-03-14 National Environmental Products, Ltd. Forced-air heater control system and method
EP1947094A3 (en) 2003-12-12 2009-02-18 Quiral Quimica Do Brasil Process for the preparation of taxane derivatives
WO2005062992A2 (en) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc Substituted melatonin derivatives, process for their preparation, and methods of use
JP2005225818A (ja) * 2004-02-13 2005-08-25 Otsuka Pharmaceut Factory Inc パクリタキセル又はドセタキセルの医薬組成物
KR20050099311A (ko) 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
US20060079672A1 (en) 2004-10-07 2006-04-13 Paul Glidden Kits for modulating angiogenesis
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1827501B2 (en) 2004-12-21 2013-11-20 Nektar Therapeutics Stabilized polymeric thiol reagents
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
CA2598510C (en) 2005-02-18 2011-12-20 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2598441A1 (en) 2005-02-24 2006-08-31 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof
US20080128314A1 (en) * 2005-03-14 2008-06-05 Koichi Takeda Pharmaceutical Composition Containing Hardly Water Soluble Medicament
CA2611592A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
TR200801336T1 (tr) * 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
KR101457834B1 (ko) 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
WO2007044950A2 (en) 2005-10-12 2007-04-19 Sicor, Inc. Crystalline forms of docetaxel and processes for their preparation
CA2642324C (en) 2006-02-21 2011-03-29 Dabur Pharma Limited Stable pharmaceutical composition of taxanes
KR20080100264A (ko) 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
JP2010502603A (ja) 2006-08-31 2010-01-28 アブラクシス バイオサイエンス， エルエルシー 血管形成を阻害し、血管形成関連疾患を処置する方法
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) * 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2007334360B2 (en) * 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
RU2483714C2 (ru) * 2007-03-07 2013-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи. Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
PT2155188E (pt) 2007-06-01 2013-12-19 Abraxis Bioscience Llc Métodos e composições para o tratamento de cancro recorrente
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
WO2010068925A1 (en) * 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20120189701A1 (en) 2009-03-13 2012-07-26 Desai Neil P Combination therapy with thiocolchicine derivatives
EP2416650B1 (en) 2009-04-10 2020-02-26 Abraxis BioScience, LLC Nanoparticle formulations and uses therof
SMT201900751T1 (it) 2009-04-15 2020-03-13 Abraxis Bioscience Llc Composizioni nanoparticellari prive di prioni e metodi
ES2577024T3 (es) * 2009-08-25 2016-07-12 Abraxis Bioscience, Llc Terapia combinada con composiciones de nanopartículas de taxano e inhibidores de Hedgehog
ES2675212T3 (es) * 2010-03-26 2018-07-09 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
US10660965B2 (en) * 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
US9393318B2 (en) * 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130109025A (ko) * 2010-06-02 2013-10-07 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
MX347225B (es) * 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
KR101850566B1 (ko) 2010-06-07 2018-04-19 아브락시스 바이오사이언스, 엘엘씨 증식성 질환의 치료를 위한 조합 치료 방법
ES2819204T3 (es) 2011-04-28 2021-04-15 Abraxis Bioscience Llc Administración intravascular de composiciones de nanopartículas y usos de las mismas
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033552A1 (en) * 1996-03-12 1997-09-18 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US20050004002A1 (en) * 2002-12-09 2005-01-06 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents

Also Published As

Publication number Publication date
RU2451510C2 (ru) 2012-05-27
EP1931321B1 (en) 2018-12-26
KR20080065600A (ko) 2008-07-14
PT1931321T (pt) 2019-05-14
SI1931321T1 (sl) 2019-07-31
PT3311805T (pt) 2020-04-21
US20110196026A1 (en) 2011-08-11
CN103054798A (zh) 2013-04-24
ES2784794T3 (es) 2020-10-01
ZA200802765B (en) 2009-08-26
CA2880727A1 (en) 2007-03-08
CA2848021A1 (en) 2007-03-08
ES2663324T3 (es) 2018-04-12
JP5461837B2 (ja) 2014-04-02
CA2880727C (en) 2019-05-07
CN101291659A (zh) 2008-10-22
CN104189905A (zh) 2014-12-10
TW200744677A (en) 2007-12-16
WO2007027819A2 (en) 2007-03-08
EP3311805A1 (en) 2018-04-25
PL3311805T3 (pl) 2020-07-27
IL189601A0 (en) 2008-08-07
CY1121461T1 (el) 2020-05-29
ES2720603T3 (es) 2019-07-23
IL189601A (en) 2016-04-21
DK3311805T3 (da) 2020-04-14
EP3311805B1 (en) 2020-01-15
TW200744639A (en) 2007-12-16
SI3311805T1 (sl) 2020-07-31
AU2006284808B2 (en) 2012-08-16
IL272235A (en) 2020-02-27
KR101420445B1 (ko) 2014-07-16
EP2404594B1 (en) 2017-12-20
NO20191301A1 (no) 2008-05-13
CA2620585A1 (en) 2007-03-08
EP2399573A1 (en) 2011-12-28
HUE048521T2 (hu) 2020-08-28
RU2433818C2 (ru) 2011-11-20
JP2013213069A (ja) 2013-10-17
WO2007027819A3 (en) 2007-04-26
PL1931321T3 (pl) 2019-08-30
LT1931321T (lt) 2019-05-10
US20120308612A1 (en) 2012-12-06
CA2848021C (en) 2016-12-13
US7771751B2 (en) 2010-08-10
HK1252388A1 (en) 2019-05-24
NZ566696A (en) 2012-03-30
TR200801337T1 (tr) 2008-07-21
CA2620585C (en) 2015-04-28
RU2008112144A (ru) 2009-10-10
US9308180B2 (en) 2016-04-12
NO343593B1 (no) 2019-04-08
US20110118342A1 (en) 2011-05-19
LT3311805T (lt) 2020-04-27
TWI429452B (zh) 2014-03-11
JP2009506126A (ja) 2009-02-12
TR200801336T1 (tr) 2008-08-21
US20110151012A1 (en) 2011-06-23
EP1931321A2 (en) 2008-06-18
CN103054798B (zh) 2021-03-16
US20190343789A1 (en) 2019-11-14
EP2404594A1 (en) 2012-01-11
US20070117744A1 (en) 2007-05-24
IL245152B (en) 2020-02-27
IL245152A0 (en) 2016-06-30
CY1123047T1 (el) 2021-10-29
EP3659589A1 (en) 2020-06-03
HUE042678T2 (hu) 2019-07-29
RU2008112146A (ru) 2009-10-10
NO345390B1 (no) 2021-01-11
EP2399573B1 (en) 2019-01-02
ES2718323T3 (es) 2019-07-01
NO20081543L (no) 2008-05-13
AU2006284808A1 (en) 2007-03-08
US20170007569A1 (en) 2017-01-12
BRPI0615265A8 (pt) 2018-03-06
DK1931321T3 (en) 2019-04-15
BRPI0615265A2 (pt) 2011-05-17

Similar Documents

Publication Publication Date Title
TWI417114B (zh) 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
US8034765B2 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
HK40012216A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
MX2008002742A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
HK1166014A (en) Compositions comprising docetaxel with increased stability
HK1119599B (en) Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof
HK1119599A (en) Compositions of poorly water soluble drugs with increased stability and methods for preparation thereof
HK1166014B (en) Compositions comprising docetaxel with increased stability
UA96273C2 (uk) Композиція доцетакселу і цитрату для лікування раку